Ralf Gutzmer
About
Ralf Gutzmer is a scholar working on Oncology, Molecular Biology and Immunology.
According to data from OpenAlex, Ralf Gutzmer has authored 346 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Oncology, 144 papers in Molecular Biology and 97 papers in Immunology. Recurrent topics in Ralf Gutzmer's work include Melanoma and MAPK Pathways (96 papers), Cutaneous Melanoma Detection and Management (91 papers) and Cancer Immunotherapy and Biomarkers (73 papers). Ralf Gutzmer is often cited by papers focused on Melanoma and MAPK Pathways (96 papers), Cutaneous Melanoma Detection and Management (91 papers) and Cancer Immunotherapy and Biomarkers (73 papers). Ralf Gutzmer collaborates with scholars based in Germany, United States and France. Ralf Gutzmer's co-authors include Alexander Kapp, Thomas Werfel, Dirk Schadendorf, Imke Satzger, Axel Hauschild, Susanne Mommert, Holger Stark, Carmen Loquai, Selma Ugurel and Carola Berking and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Ralf Gutzmer
327 papers receiving 11.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ralf Gutzmer Germany | 52 | 6.5k | 5.1k | 3.4k | 2.0k | 1.8k | 346 | 11.9k | ||
| Antonio Costanzo Italy | 54 | 3.5k 0.5× | 4.6k 0.9× | 3.6k 1.1× | 2.2k 1.1× | 1.1k 0.6× | 288 | 10.7k | ||
| Hensin Tsao United States | 50 | 5.5k 0.9× | 5.1k 1.0× | 1.7k 0.5× | 1.4k 0.7× | 1.1k 0.6× | 191 | 9.6k | ||
| Carola Berking Germany | 50 | 5.5k 0.9× | 4.0k 0.8× | 1.8k 0.5× | 1.8k 0.9× | 2.1k 1.2× | 319 | 10.5k | ||
| Erin Murphy United States | 22 | 6.2k 1.0× | 3.0k 0.6× | 8.4k 2.5× | 777 0.4× | 736 0.4× | 49 | 13.9k | ||
| Jane L. Messina United States | 53 | 5.6k 0.9× | 2.9k 0.6× | 2.1k 0.6× | 1.1k 0.6× | 1.8k 1.0× | 260 | 9.6k | ||
| Alberto Órfão Spain | 66 | 3.1k 0.5× | 4.5k 0.9× | 5.8k 1.7× | 563 0.3× | 1.5k 0.8× | 463 | 16.1k | ||
| Stéphane Dalle France | 52 | 4.0k 0.6× | 3.0k 0.6× | 1.6k 0.5× | 1.8k 0.9× | 2.0k 1.1× | 325 | 9.1k | ||
| Friedegund Meier Germany | 48 | 3.9k 0.6× | 3.7k 0.7× | 1.3k 0.4× | 594 0.3× | 762 0.4× | 218 | 7.4k | ||
| Brian J. Nickoloff United States | 76 | 4.4k 0.7× | 5.3k 1.0× | 9.1k 2.7× | 5.6k 2.9× | 1.7k 1.0× | 239 | 19.0k | ||
| Jochen Utikal Germany | 60 | 6.4k 1.0× | 8.9k 1.8× | 4.4k 1.3× | 526 0.3× | 827 0.5× | 277 | 16.7k |
Countries citing papers authored by Ralf Gutzmer
Since
Specialization
Citations
This map shows the geographic impact of Ralf Gutzmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf Gutzmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf Gutzmer more than expected).
Fields of papers citing papers by Ralf Gutzmer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ralf Gutzmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf Gutzmer. The network helps show where Ralf Gutzmer may publish in the future.
Co-authorship network of co-authors of Ralf Gutzmer
This figure shows the co-authorship network connecting the top 25 collaborators of Ralf Gutzmer. A scholar is included among the top collaborators of Ralf Gutzmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf Gutzmer. Ralf Gutzmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schadendorf, Dirk, Caroline Robert, Ana Arance, et al.. (2024). COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European Journal of Cancer. 204. 114073–114073.
2.
Nikolouli, Eirini, Susanne Mommert, Holger Stark, et al.. (2024). The stimulation of TH2 cells results in increased IL ‐5 and IL ‐13 production via the H4 receptor. Allergy. 79(8). 2186–2196.
3.
Becker, Jürgen C., Andreas Stang, David Schrama, Ralf Gutzmer, & Selma Ugurel. (2024). Update Merkel-Zell-Karzinom. PUBLISSO (German National Library of Medicine). 30(9). 863–872.
4.
Schadendorf, Dirk, Reinhard Dummer, K. T. Flaherty, et al.. (2023). 1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma. Annals of Oncology. 34. S670–S671.
5.
Surov, Alexey, Andreas Wienke, Ralf Gutzmer, & Jan Borggrefe. (2023). Prognostic role of the skeletal musculature in oncology: significance, coherences and clinical implications. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 196(7). 699–706.
6.
Hassel, Jessica C., Lisa Zimmer, Thomas Eigentler, et al.. (2023). Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers. 15(13). 3448–3448.
7.
Kimmig, Martin, Klaus Griewank, Eva Hadaschik, et al.. (2023). 1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined. Annals of Oncology. 34. S695–S695.
8.
Haydon, Andrew, Dirk Schadendorf, Reinhard Dummer, et al.. (2023). 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 34. S1707–S1708.
9.
Bossi, Paolo, Paolo A. Ascierto, Nicole Basset‐Séguin, et al.. (2023). Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Critical Reviews in Oncology/Hematology. 189. 104066–104066.
10.
Ascierto, Paolo A., Reinhard Dummer, Helen Gogas, et al.. (2023). Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology. 41(29). 4621–4631.
11.
Möhn, Nora, Lea Grote‐Levi, Tabea Seeliger, et al.. (2023). Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity. Cancer Medicine. 12(8). 9373–9383.
12.
Mikuteit, Marie, Anne Cossmann, Ralf Gutzmer, et al.. (2022). Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade. Oncology. 100(7). 392–398.
13.
Malvehy, Josep, Dirk Schadendorf, Ralf Gutzmer, et al.. (2021). Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma. Journal for ImmunoTherapy of Cancer. 9(3). e001621–e001621.
14.
Möhn, Nora, Kurt‐Wolfram Sühs, Martin Stangel, et al.. (2021). Checkpoint inhibitor–induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin’s lymphoma. Clinical and Experimental Neuroimmunology. 12(2). 127–134.
15.
Möhn, Nora, Ralf Gutzmer, Imke Satzger, et al.. (2020). Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. Journal of Oncology. 2020. 1–9.
16.
Gutzmer, Ralf & Jürgen C. Becker. (2019). Neues zum kutanen Plattenepithelkarzinom. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 17(10). 1097–1098.
17.
Weide, Benjamin, Thomas Eigentler, Annette Pflugfelder, et al.. (2014). Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses. Cancer Immunology Research. 2(7). 668–678.
18.
Gschwandtner, Maria, Michael Mildner, Veronika Mlitz, et al.. (2012). Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy. 68(1). 37–47.
19.
Gschwandtner, Maria, Kristine Roßbach, Dorothea Dijkstra, et al.. (2009). Murine and human Langerhans cells express a functional histamine H4 receptor: modulation of cell migration and function. Allergy. 65(7). 840–849.
20.
Purwar, Rahul, Miriam Wittmann, Jörg Zwirner, et al.. (2006). Induction of C3 and CCL2 by C3a in Keratinocytes: A Novel Autocrine Amplification Loop of Inflammatory Skin Reactions. The Journal of Immunology. 177(7). 4444–4450.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Antonio Costanzo Breakdown of academic impact, for papers by Hensin Tsao Breakdown of academic impact, for papers by Carola Berking Breakdown of academic impact, for papers by Erin Murphy Breakdown of academic impact, for papers by Jane L. Messina Breakdown of academic impact, for papers by Alberto Órfão Breakdown of academic impact, for papers by Stéphane Dalle Breakdown of academic impact, for papers by Friedegund Meier Breakdown of academic impact, for papers by Brian J. Nickoloff Breakdown of academic impact, for papers by Jochen Utikal